Last reviewed · How we verify
Tislelizumab and nintedanib
Tislelizumab blocks PD-1 to enhance anti-tumor immunity, while nintedanib inhibits multiple receptor tyrosine kinases to reduce angiogenesis and fibrosis.
Tislelizumab blocks PD-1 to enhance anti-tumor immunity, while nintedanib inhibits multiple receptor tyrosine kinases to reduce angiogenesis and fibrosis. Used for Non-small cell lung cancer (NSCLC) with specific molecular or histological subtypes.
At a glance
| Generic name | Tislelizumab and nintedanib |
|---|---|
| Sponsor | The Affiliated Hospital of Qingdao University |
| Drug class | PD-1 inhibitor + tyrosine kinase inhibitor combination |
| Target | PD-1 (tislelizumab); VEGFR, FGFR, PDGFR (nintedanib) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Tislelizumab is a humanized anti-PD-1 monoclonal antibody that restores T-cell-mediated immune responses against cancer cells. Nintedanib is a small-molecule tyrosine kinase inhibitor targeting VEGFR, FGFR, and PDGFR, which suppresses tumor angiogenesis and fibroblast-mediated stromal remodeling. The combination aims to synergize immunotherapy with anti-angiogenic and anti-fibrotic effects.
Approved indications
- Non-small cell lung cancer (NSCLC) with specific molecular or histological subtypes
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Decreased appetite
- Immune-related adverse events (e.g., pneumonitis, hepatitis)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: